{"product_id":"bioglutide","title":"Bioglutide 100x100mg","description":"\u003cp data-start=\"0\" data-end=\"404\"\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eNOT FOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"0\" data-end=\"404\"\u003e\u003cstrong data-start=\"0\" data-end=\"51\"\u003eBioglutide (NA-931) \u003c\/strong\u003e is positioned as a \u003cstrong data-start=\"465\" data-end=\"484\"\u003eonce-daily pill\u003c\/strong\u003e aiming to combine \u003cstrong data-start=\"503\" data-end=\"541\"\u003eincretin satiety\/glycaemic control\u003c\/strong\u003e (GLP-1, GIP), \u003cstrong data-start=\"556\" data-end=\"596\"\u003eenergy-expenditure and hepatic lipid\u003c\/strong\u003e effects (glucagon), and \u003cstrong data-start=\"621\" data-end=\"652\"\u003eanabolism\/lean-mass support\u003c\/strong\u003e (claimed IGF-1 receptor activity). If verified, the mix would theoretically pair \u003cstrong data-start=\"734\" data-end=\"763\"\u003edeep appetite suppression\u003c\/strong\u003e with \u003cstrong data-start=\"769\" data-end=\"798\"\u003ehigher energy expenditure\u003c\/strong\u003e and \u003cstrong data-start=\"803\" data-end=\"838\"\u003ebetter body-composition quality\u003c\/strong\u003e than GLP-1 monotherapy. Evidence confirming \u003cstrong data-start=\"883\" data-end=\"936\"\u003edirect IGF-1 receptor agonism by a small molecule\u003c\/strong\u003e is sparse in the literature, so this aspect should be viewed as \u003cstrong data-start=\"1001\" data-end=\"1013\"\u003eunproven\u003c\/strong\u003e pending peer-review. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1074\" data-end=\"1077\"\u003e\n\u003ch3 data-start=\"1079\" data-end=\"1140\"\u003eAdditional Benefits of Bioglutide Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"1142\" data-end=\"3350\" class=\"w-fit min-w-(--thread-content-width)\" style=\"width: 100%; height: 569px;\"\u003e\n\u003cthead data-start=\"1142\" data-end=\"1170\"\u003e\n\u003ctr data-start=\"1142\" data-end=\"1170\" style=\"height: 19px;\"\u003e\n\u003cth data-start=\"1142\" data-end=\"1152\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 19px;\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"1152\" data-end=\"1170\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 19px;\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1181\" data-end=\"3350\"\u003e\n\u003ctr data-start=\"1181\" data-end=\"1466\" style=\"height: 75px;\"\u003e\n\u003ctd data-start=\"1181\" data-end=\"1221\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 75px;\"\u003e\u003cstrong data-start=\"1183\" data-end=\"1220\"\u003e1 Oral, multi-pathway weight loss\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1221\" data-end=\"1466\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 75px;\"\u003eCompany-reported Phase 2 data (13 weeks) cite \u003cstrong data-start=\"1269\" data-end=\"1302\"\u003edouble-digit mean weight loss\u003c\/strong\u003e at higher doses, with \u003cstrong data-start=\"1325\" data-end=\"1361\"\u003eplacebo-adjusted reductions \u0026gt;10%\u003c\/strong\u003e in top arms. Independent, peer-reviewed confirmation is pending. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1467\" data-end=\"1691\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"1467\" data-end=\"1500\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"1469\" data-end=\"1499\"\u003e2 Glycaemic control in T2D\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1500\" data-end=\"1691\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eAims to deliver \u003cstrong data-start=\"1518\" data-end=\"1536\"\u003eA1c reductions\u003c\/strong\u003e comparable to injectable incretins while being oral; formal peer-reviewed T2D results have not yet been published. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1692\" data-end=\"2008\" style=\"height: 76px;\"\u003e\n\u003ctd data-start=\"1692\" data-end=\"1732\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 76px;\"\u003e\u003cstrong data-start=\"1694\" data-end=\"1731\"\u003e3 Energy-expenditure boost (GCGR)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1732\" data-end=\"2008\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 76px;\"\u003eGlucagon receptor engagement is expected to \u003cstrong data-start=\"1778\" data-end=\"1814\"\u003eraise resting energy expenditure\u003c\/strong\u003e and \u003cstrong data-start=\"1819\" data-end=\"1844\"\u003epromote fat oxidation\u003c\/strong\u003e, potentially countering metabolic adaptation seen with weight loss. Human EE data for NA-931 have not been publicly vetted. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2009\" data-end=\"2252\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2009\" data-end=\"2051\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2011\" data-end=\"2050\"\u003e4 Lean-mass preservation (IGF-axis)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2051\" data-end=\"2252\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eBy adding an IGF-1 component, NA-931 is pitched to \u003cstrong data-start=\"2104\" data-end=\"2123\"\u003epreserve muscle\u003c\/strong\u003e during weight loss; \u003cstrong data-start=\"2144\" data-end=\"2163\"\u003edirect evidence\u003c\/strong\u003e in humans has not been disclosed in peer-review. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2253\" data-end=\"2512\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2253\" data-end=\"2286\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2255\" data-end=\"2285\"\u003e5 Liver fat \u0026amp; MASH signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2286\" data-end=\"2512\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eA quadruple profile could reduce \u003cstrong data-start=\"2321\" data-end=\"2333\"\u003eMRI-PDFF\u003c\/strong\u003e and improve \u003cstrong data-start=\"2346\" data-end=\"2357\"\u003eALT\/AST\u003c\/strong\u003e (weight loss + glucagon hepatolipid effects); trials in metabolic liver disease are referenced as ongoing\/planned. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2513\" data-end=\"2711\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2513\" data-end=\"2545\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2515\" data-end=\"2544\"\u003e6 Convenience \u0026amp; adherence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2545\" data-end=\"2711\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003e\n\u003cstrong data-start=\"2547\" data-end=\"2555\"\u003eOral\u003c\/strong\u003e dosing may improve \u003cstrong data-start=\"2575\" data-end=\"2601\"\u003euptake and persistence\u003c\/strong\u003e vs injectables for some patients, assuming tolerability is favorable. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2712\" data-end=\"2946\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2712\" data-end=\"2742\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2714\" data-end=\"2741\"\u003e7 Combination potential\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2742\" data-end=\"2946\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eCompany materials suggest \u003cstrong data-start=\"2770\" data-end=\"2780\"\u003eadd-on\u003c\/strong\u003e use with GLP-1\/GIP injectables (e.g., semaglutide\/tirzepatide) for extra weight loss; this is \u003cstrong data-start=\"2875\" data-end=\"2900\"\u003ehypothesis-generating\u003c\/strong\u003e only. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2947\" data-end=\"3173\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2947\" data-end=\"2984\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2949\" data-end=\"2983\"\u003e8 Cardiometabolic risk factors\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2984\" data-end=\"3173\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eExpectation (by mechanism\/class): \u003cstrong data-start=\"3020\" data-end=\"3043\"\u003eBP and triglyceride\u003c\/strong\u003e reductions, \u003cstrong data-start=\"3056\" data-end=\"3072\"\u003enon-HDL\/apoB\u003c\/strong\u003e improvements; formal datasets for NA-931 are not yet public. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3174\" data-end=\"3350\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"3174\" data-end=\"3208\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"3176\" data-end=\"3207\"\u003e9 Patient-reported outcomes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3208\" data-end=\"3350\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eAnticipated gains in \u003cstrong data-start=\"3231\" data-end=\"3271\"\u003esatiety, cravings, physical function\u003c\/strong\u003e—data not yet peer-reviewed for NA-931. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3352\" data-end=\"3355\"\u003e\n\u003ch2 data-start=\"3357\" data-end=\"3392\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3394\" data-end=\"3437\"\u003e2.1 Receptor pharmacodynamics (claimed)\u003c\/h3\u003e\n\u003cul data-start=\"3438\" data-end=\"4101\"\u003e\n\u003cli data-start=\"3438\" data-end=\"3542\"\u003e\n\u003cp data-start=\"3440\" data-end=\"3542\"\u003e\u003cstrong data-start=\"3440\" data-end=\"3451\"\u003eGLP-1R:\u003c\/strong\u003e ↓ appetite, ↓ gastric emptying; glucose-dependent \u003cstrong data-start=\"3502\" data-end=\"3514\"\u003einsulin↑\u003c\/strong\u003e, \u003cstrong data-start=\"3516\" data-end=\"3529\"\u003eglucagon↓\u003c\/strong\u003e post-meal.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3543\" data-end=\"3671\"\u003e\n\u003cp data-start=\"3545\" data-end=\"3671\"\u003e\u003cstrong data-start=\"3545\" data-end=\"3554\"\u003eGIPR:\u003c\/strong\u003e Potentiates insulin secretion; may improve \u003cstrong data-start=\"3598\" data-end=\"3633\"\u003eadipocyte metabolic flexibility\u003c\/strong\u003e and \u003cstrong data-start=\"3638\" data-end=\"3657\"\u003eGI tolerability\u003c\/strong\u003e with GLP-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3672\" data-end=\"3804\"\u003e\n\u003cp data-start=\"3674\" data-end=\"3804\"\u003e\u003cstrong data-start=\"3674\" data-end=\"3694\"\u003eGCGR (glucagon):\u003c\/strong\u003e \u003cstrong data-start=\"3695\" data-end=\"3719\"\u003e↑ energy expenditure\u003c\/strong\u003e and fat oxidation; mobilizes hepatic lipid with careful glycaemic counter-balance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3805\" data-end=\"4101\"\u003e\n\u003cp data-start=\"3807\" data-end=\"4101\"\u003e\u003cstrong data-start=\"3807\" data-end=\"3828\"\u003eIGF-1R (claimed):\u003c\/strong\u003e \u003cstrong data-start=\"3829\" data-end=\"3856\"\u003eAnabolic\/anti-catabolic\u003c\/strong\u003e signaling (Akt–mTOR); preservation of \u003cstrong data-start=\"3895\" data-end=\"3908\"\u003elean mass\u003c\/strong\u003e. \u003cem data-start=\"3910\" data-end=\"3917\"\u003eNote:\u003c\/em\u003e \u003cstrong data-start=\"3918\" data-end=\"3969\"\u003eDirect, selective small-molecule IGF-1R agonism\u003c\/strong\u003e is biologically unusual and currently \u003cstrong data-start=\"4008\" data-end=\"4022\"\u003eunverified\u003c\/strong\u003e for NA-931 outside company statements. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4103\" data-end=\"4130\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4132\" data-end=\"4507\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4132\" data-end=\"4174\"\u003e\n\u003ctr data-start=\"4132\" data-end=\"4174\"\u003e\n\u003cth data-start=\"4132\" data-end=\"4142\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"4142\" data-end=\"4163\" data-col-size=\"sm\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"4163\" data-end=\"4174\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4189\" data-end=\"4507\"\u003e\n\u003ctr data-start=\"4189\" data-end=\"4256\"\u003e\n\u003ctd data-start=\"4189\" data-end=\"4211\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4191\" data-end=\"4210\"\u003ePOMC\/AgRP (CNS)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4211\" data-end=\"4235\" data-col-size=\"sm\"\u003eSatiety ↑, cravings ↓\u003c\/td\u003e\n\u003ctd data-start=\"4235\" data-end=\"4256\" data-col-size=\"sm\"\u003eAppetite circuits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4257\" data-end=\"4330\"\u003e\n\u003ctd data-start=\"4257\" data-end=\"4288\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4259\" data-end=\"4287\"\u003eIslet incretin signaling\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4288\" data-end=\"4318\" data-col-size=\"sm\"\u003eGlucose-dependent insulin ↑\u003c\/td\u003e\n\u003ctd data-start=\"4318\" data-end=\"4330\" data-col-size=\"sm\"\u003ePancreas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4331\" data-end=\"4407\"\u003e\n\u003ctd data-start=\"4331\" data-end=\"4367\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4333\" data-end=\"4366\"\u003eHepatic lipid handling (GCGR)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4367\" data-end=\"4398\" data-col-size=\"sm\"\u003eFat oxidation ↑, steatosis ↓\u003c\/td\u003e\n\u003ctd data-start=\"4398\" data-end=\"4407\" data-col-size=\"sm\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4408\" data-end=\"4507\"\u003e\n\u003ctd data-start=\"4408\" data-end=\"4434\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4410\" data-end=\"4433\"\u003eAkt–mTOR (IGF-axis)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4434\" data-end=\"4472\" data-col-size=\"sm\"\u003eProtein synthesis\/lean mass support\u003c\/td\u003e\n\u003ctd data-start=\"4472\" data-end=\"4507\" data-col-size=\"sm\"\u003eMuscle (theoretical for NA-931)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"4509\" data-end=\"4512\"\u003e\n\u003ch2 data-start=\"4514\" data-end=\"4536\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"4538\" data-end=\"4876\"\u003e\n\u003cli data-start=\"4538\" data-end=\"4611\"\u003e\n\u003cp data-start=\"4540\" data-end=\"4611\"\u003e\u003cstrong data-start=\"4540\" data-end=\"4562\"\u003eFormulation\/Route:\u003c\/strong\u003e \u003cstrong data-start=\"4563\" data-end=\"4578\"\u003eOral tablet\u003c\/strong\u003e, once daily (company reports).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4612\" data-end=\"4728\"\u003e\n\u003cp data-start=\"4614\" data-end=\"4728\"\u003e\u003cstrong data-start=\"4614\" data-end=\"4637\"\u003eHalf-life\/Exposure:\u003c\/strong\u003e Not published in peer-review; dose-ranging has been presented in company communications.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4729\" data-end=\"4785\"\u003e\n\u003cp data-start=\"4731\" data-end=\"4785\"\u003e\u003cstrong data-start=\"4731\" data-end=\"4758\"\u003eFood effect\/Absorption:\u003c\/strong\u003e Not disclosed in detail.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4786\" data-end=\"4876\"\u003e\n\u003cp data-start=\"4788\" data-end=\"4876\"\u003e\u003cstrong data-start=\"4788\" data-end=\"4802\"\u003eDrug–drug:\u003c\/strong\u003e No public interaction matrix yet. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4878\" data-end=\"4881\"\u003e\n\u003ch2 data-start=\"4883\" data-end=\"4937\"\u003e4. Pre-clinical \u0026amp; Clinical Evidence (what’s public)\u003c\/h2\u003e\n\u003cul data-start=\"4939\" data-end=\"5433\"\u003e\n\u003cli data-start=\"4939\" data-end=\"5228\"\u003e\n\u003cp data-start=\"4941\" data-end=\"5228\"\u003e\u003cstrong data-start=\"4941\" data-end=\"4980\"\u003ePhase 2 obesity (company-reported):\u003c\/strong\u003e ~\u003cstrong data-start=\"4982\" data-end=\"4993\"\u003e13-week\u003c\/strong\u003e study with \u003cstrong data-start=\"5005\" data-end=\"5035\"\u003edose-dependent weight loss\u003c\/strong\u003e; a high-dose arm reportedly \u003cstrong data-start=\"5064\" data-end=\"5103\"\u003e~14–15% total body-weight reduction\u003c\/strong\u003e and \u003cstrong data-start=\"5108\" data-end=\"5133\"\u003e~13% placebo-adjusted\u003c\/strong\u003e—awaiting peer-review and full protocol transparency. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5229\" data-end=\"5433\"\u003e\n\u003cp data-start=\"5231\" data-end=\"5433\"\u003e\u003cstrong data-start=\"5231\" data-end=\"5254\"\u003eDevelopment status:\u003c\/strong\u003e Communicated as moving toward \u003cstrong data-start=\"5285\" data-end=\"5299\"\u003ePhase 2b\/3\u003c\/strong\u003e in \u003cstrong data-start=\"5303\" data-end=\"5318\"\u003eobesity\/T2D\u003c\/strong\u003e; registry and pipeline round-ups list NA-931 in \u003cstrong data-start=\"5367\" data-end=\"5380\"\u003emid-stage\u003c\/strong\u003e development. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"5435\" data-end=\"5687\"\u003e\n\u003cp data-start=\"5437\" data-end=\"5687\"\u003e\u003cstrong data-start=\"5437\" data-end=\"5463\"\u003eEvidence quality note:\u003c\/strong\u003e To date, \u003cstrong data-start=\"5473\" data-end=\"5499\"\u003enearly all information\u003c\/strong\u003e comes from \u003cstrong data-start=\"5511\" data-end=\"5537\"\u003ecompany press releases\u003c\/strong\u003e, \u003cstrong data-start=\"5539\" data-end=\"5566\"\u003eindustry trade coverage\u003c\/strong\u003e, or \u003cstrong data-start=\"5571\" data-end=\"5593\"\u003epipeline summaries\u003c\/strong\u003e—not peer-reviewed journals. Treat efficacy magnitudes and receptor claims as \u003cstrong data-start=\"5671\" data-end=\"5686\"\u003epreliminary\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5689\" data-end=\"5692\"\u003e\n\u003ch2 data-start=\"5694\" data-end=\"5727\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5729\" data-end=\"6163\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5729\" data-end=\"5759\"\u003e\n\u003ctr data-start=\"5729\" data-end=\"5759\"\u003e\n\u003cth data-start=\"5729\" data-end=\"5737\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5737\" data-end=\"5749\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5749\" data-end=\"5759\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5774\" data-end=\"6163\"\u003e\n\u003ctr data-start=\"5774\" data-end=\"5878\"\u003e\n\u003ctd data-start=\"5774\" data-end=\"5806\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5776\" data-end=\"5805\"\u003eChronic weight management\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5806\" data-end=\"5852\" data-col-size=\"md\"\u003eOral option with multi-hormone pharmacology\u003c\/td\u003e\n\u003ctd data-start=\"5852\" data-end=\"5878\" data-col-size=\"sm\"\u003ePhase 2→2b\/3 (company)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5879\" data-end=\"5981\"\u003e\n\u003ctd data-start=\"5879\" data-end=\"5901\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5881\" data-end=\"5900\"\u003eType 2 diabetes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5901\" data-end=\"5950\" data-col-size=\"md\"\u003eA1c + weight + potential metabolic flexibility\u003c\/td\u003e\n\u003ctd data-start=\"5950\" data-end=\"5981\" data-col-size=\"sm\"\u003ePlanned\/ongoing per company\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5982\" data-end=\"6063\"\u003e\n\u003ctd data-start=\"5982\" data-end=\"5999\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5984\" data-end=\"5998\"\u003eMASH\/NAFLD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5999\" data-end=\"6048\" data-col-size=\"md\"\u003eWeight + glucagon-driven hepatic lipid effects\u003c\/td\u003e\n\u003ctd data-start=\"6048\" data-end=\"6063\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6064\" data-end=\"6163\"\u003e\n\u003ctd data-start=\"6064\" data-end=\"6099\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6066\" data-end=\"6098\"\u003eCombination with injectables\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6099\" data-end=\"6133\" data-col-size=\"md\"\u003eAdditive weight loss hypothesis\u003c\/td\u003e\n\u003ctd data-start=\"6133\" data-end=\"6163\" data-col-size=\"sm\"\u003ePreclinical\/company claims\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6165\" data-end=\"6168\"\u003e\n\u003ch2 data-start=\"6170\" data-end=\"6236\"\u003e6. Safety and Tolerability (what to expect, what we don’t know)\u003c\/h2\u003e\n\u003cul data-start=\"6238\" data-end=\"7065\"\u003e\n\u003cli data-start=\"6238\" data-end=\"6379\"\u003e\n\u003cp data-start=\"6240\" data-end=\"6379\"\u003e\u003cstrong data-start=\"6240\" data-end=\"6284\"\u003eLikely class AEs (if incretin-dominant):\u003c\/strong\u003e \u003cstrong data-start=\"6285\" data-end=\"6328\"\u003eNausea, vomiting, diarrhea\/constipation\u003c\/strong\u003e, abdominal pain (generally titration-dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6380\" data-end=\"6509\"\u003e\n\u003cp data-start=\"6382\" data-end=\"6509\"\u003e\u003cstrong data-start=\"6382\" data-end=\"6405\"\u003eGlucagon component:\u003c\/strong\u003e Possible \u003cstrong data-start=\"6415\" data-end=\"6431\"\u003e↑ heart rate\u003c\/strong\u003e, \u003cstrong data-start=\"6433\" data-end=\"6463\"\u003eglycaemic counter-pressure\u003c\/strong\u003e (balanced by GLP-1\/GIP); monitor \u003cstrong data-start=\"6497\" data-end=\"6506\"\u003eBP\/HR\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6510\" data-end=\"6702\"\u003e\n\u003cp data-start=\"6512\" data-end=\"6702\"\u003e\u003cstrong data-start=\"6512\" data-end=\"6548\"\u003eIGF-axis concerns (theoretical):\u003c\/strong\u003e If genuine IGF-1R agonism occurs, watch \u003cstrong data-start=\"6589\" data-end=\"6598\"\u003eedema\u003c\/strong\u003e, \u003cstrong data-start=\"6600\" data-end=\"6628\"\u003ehypoglycaemia (low risk)\u003c\/strong\u003e, and \u003cstrong data-start=\"6634\" data-end=\"6657\"\u003emitogenic signaling\u003c\/strong\u003e—though this is \u003cstrong data-start=\"6673\" data-end=\"6688\"\u003eunconfirmed\u003c\/strong\u003e for NA-931.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6703\" data-end=\"6846\"\u003e\n\u003cp data-start=\"6705\" data-end=\"6846\"\u003e\u003cstrong data-start=\"6705\" data-end=\"6718\"\u003eUnknowns:\u003c\/strong\u003e \u003cstrong data-start=\"6719\" data-end=\"6739\"\u003eLong-term safety\u003c\/strong\u003e, \u003cstrong data-start=\"6741\" data-end=\"6756\"\u003egallbladder\u003c\/strong\u003e events with large weight loss, \u003cstrong data-start=\"6788\" data-end=\"6809\"\u003epancreato-biliary\u003c\/strong\u003e risks, \u003cstrong data-start=\"6817\" data-end=\"6843\"\u003edrug–drug interactions\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6847\" data-end=\"7065\"\u003e\n\u003cp data-start=\"6849\" data-end=\"7065\"\u003e\u003cstrong data-start=\"6849\" data-end=\"6898\"\u003eContraindications\/caution (by class analogy):\u003c\/strong\u003e History of \u003cstrong data-start=\"6910\" data-end=\"6922\"\u003eMEN2\/MTC\u003c\/strong\u003e (GLP-1 class warning), \u003cstrong data-start=\"6946\" data-end=\"6963\"\u003egastroparesis\u003c\/strong\u003e, pregnancy. Final labeling, if any, will determine specifics. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"7067\" data-end=\"7103\"\u003e\u003cstrong data-start=\"7067\" data-end=\"7103\"\u003eComparative snapshot (tentative)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"7105\" data-end=\"7544\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"7105\" data-end=\"7178\"\u003e\n\u003ctr data-start=\"7105\" data-end=\"7178\"\u003e\n\u003cth data-start=\"7105\" data-end=\"7115\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"7115\" data-end=\"7141\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7117\" data-end=\"7140\"\u003eBioglutide (NA-931)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7141\" data-end=\"7159\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7143\" data-end=\"7158\"\u003eTirzepatide\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7159\" data-end=\"7178\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7161\" data-end=\"7176\"\u003eSemaglutide\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7197\" data-end=\"7544\"\u003e\n\u003ctr data-start=\"7197\" data-end=\"7284\"\u003e\n\u003ctd data-start=\"7197\" data-end=\"7208\" data-col-size=\"sm\"\u003eModality\u003c\/td\u003e\n\u003ctd data-start=\"7208\" data-end=\"7234\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7210\" data-end=\"7233\"\u003eOral small molecule\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7234\" data-end=\"7255\" data-col-size=\"sm\"\u003eInjectable peptide\u003c\/td\u003e\n\u003ctd data-start=\"7255\" data-end=\"7284\" data-col-size=\"sm\"\u003eOral \u0026amp; injectable peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7285\" data-end=\"7357\"\u003e\n\u003ctd data-start=\"7285\" data-end=\"7295\" data-col-size=\"sm\"\u003eTargets\u003c\/td\u003e\n\u003ctd data-start=\"7295\" data-end=\"7334\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7297\" data-end=\"7333\"\u003eGLP-1\/GIP\/GCGR + IGF-1 (claimed)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7334\" data-end=\"7348\" data-col-size=\"sm\"\u003eGLP-1 + GIP\u003c\/td\u003e\n\u003ctd data-start=\"7348\" data-end=\"7357\" data-col-size=\"sm\"\u003eGLP-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7358\" data-end=\"7485\"\u003e\n\u003ctd data-start=\"7358\" data-end=\"7382\" data-col-size=\"sm\"\u003eWeight-loss magnitude\u003c\/td\u003e\n\u003ctd data-start=\"7382\" data-end=\"7428\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7384\" data-end=\"7427\"\u003eCompany-reported double-digit at 13 wks\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7428\" data-end=\"7454\" data-col-size=\"sm\"\u003e15–22% at 72 wks (RCTs)\u003c\/td\u003e\n\u003ctd data-start=\"7454\" data-end=\"7485\" data-col-size=\"sm\"\u003e12–17% at 68–104 wks (RCTs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7486\" data-end=\"7544\"\u003e\n\u003ctd data-start=\"7486\" data-end=\"7511\" data-col-size=\"sm\"\u003ePeer-reviewed evidence\u003c\/td\u003e\n\u003ctd data-start=\"7511\" data-end=\"7525\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7513\" data-end=\"7524\"\u003eNot yet\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7525\" data-end=\"7534\" data-col-size=\"sm\"\u003eRobust\u003c\/td\u003e\n\u003ctd data-start=\"7534\" data-end=\"7544\" data-col-size=\"sm\"\u003eRobust\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7546\" data-end=\"7549\"\u003e\n\u003ch2 data-start=\"7551\" data-end=\"7577\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7579\" data-end=\"7805\"\u003e\n\u003cli data-start=\"7579\" data-end=\"7632\"\u003e\n\u003cp data-start=\"7581\" data-end=\"7632\"\u003e\u003cstrong data-start=\"7581\" data-end=\"7597\"\u003eNot approved\u003c\/strong\u003e by FDA\/EMA; \u003cstrong data-start=\"7610\" data-end=\"7629\"\u003einvestigational\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7633\" data-end=\"7805\"\u003e\n\u003cp data-start=\"7635\" data-end=\"7805\"\u003ePublic materials describe \u003cstrong data-start=\"7661\" data-end=\"7677\"\u003ePhase 2→2b\/3\u003c\/strong\u003e programs in \u003cstrong data-start=\"7690\" data-end=\"7701\"\u003eobesity\u003c\/strong\u003e and \u003cstrong data-start=\"7706\" data-end=\"7713\"\u003eT2D\u003c\/strong\u003e, with additional studies proposed (e.g., \u003cstrong data-start=\"7755\" data-end=\"7763\"\u003eMASH\u003c\/strong\u003e). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/www.primetherapeutics.com\/w\/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.primetherapeutics.com\/w\/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7807\" data-end=\"7810\"\u003e\n\u003ch2 data-start=\"7812\" data-end=\"7842\"\u003e8. Practical Take \u003c\/h2\u003e\n\u003cul data-start=\"7844\" data-end=\"8346\"\u003e\n\u003cli data-start=\"7844\" data-end=\"7971\"\u003e\n\u003cp data-start=\"7846\" data-end=\"7971\"\u003e\u003cstrong data-start=\"7846\" data-end=\"7867\"\u003ePromising concept\u003c\/strong\u003e, but \u003cstrong data-start=\"7873\" data-end=\"7897\"\u003eextraordinary claims\u003c\/strong\u003e (quadruple agonism incl. \u003cstrong data-start=\"7923\" data-end=\"7933\"\u003eIGF-1R\u003c\/strong\u003e) demand \u003cstrong data-start=\"7942\" data-end=\"7968\"\u003eextraordinary evidence\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7972\" data-end=\"8172\"\u003e\n\u003cp data-start=\"7974\" data-end=\"8172\"\u003eUntil \u003cstrong data-start=\"7980\" data-end=\"8011\"\u003epeer-reviewed trial reports\u003c\/strong\u003e with detailed methods, safety tables, pharmacokinetics, and receptor pharmacology are available, treat Bioglutide’s efficacy and mechanism as \u003cstrong data-start=\"8154\" data-end=\"8169\"\u003eprovisional\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8173\" data-end=\"8346\"\u003e\n\u003cp data-start=\"8175\" data-end=\"8346\"\u003eFor patients today, \u003cstrong data-start=\"8195\" data-end=\"8226\"\u003eapproved incretin therapies\u003c\/strong\u003e (semaglutide, tirzepatide, etc.) remain the \u003cstrong data-start=\"8271\" data-end=\"8289\"\u003eevidence-based\u003c\/strong\u003echoices; Bioglutide is a \u003cstrong data-start=\"8315\" data-end=\"8335\"\u003ewatch-this-space\u003c\/strong\u003e candidate.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8348\" data-end=\"8351\"\u003e\n\u003ch3 data-start=\"8353\" data-end=\"8376\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8378\" data-end=\"9089\"\u003e\n\u003cli data-start=\"8378\" data-end=\"8574\"\u003e\n\u003cp data-start=\"8380\" data-end=\"8574\"\u003e\u003cstrong data-start=\"8380\" data-end=\"8402\"\u003eCompany materials:\u003c\/strong\u003e Biomed Industries—NA-931 (Bioglutide) product page, press releases, and Phase-2 summaries (quadruple agonist, oral, obesity\/T2D). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8575\" data-end=\"8717\"\u003e\n\u003cp data-start=\"8577\" data-end=\"8717\"\u003e\u003cstrong data-start=\"8577\" data-end=\"8599\"\u003eIndustry coverage:\u003c\/strong\u003e FirstWord Pharma news on NA-931 program updates and claimed trial readouts. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/firstwordpharma.com\/story\/5991011?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/firstwordpharma.com\/story\/5991011?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8718\" data-end=\"8929\"\u003e\n\u003cp data-start=\"8720\" data-end=\"8929\"\u003e\u003cstrong data-start=\"8720\" data-end=\"8743\"\u003ePipeline round-ups:\u003c\/strong\u003e Prime Therapeutics GLP-1 pipeline brief; Larvol Delta product tracker; Patsnap\/Synapse drug entry summarizing company-reported Phase 2 figures. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/www.primetherapeutics.com\/w\/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.primetherapeutics.com\/w\/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8930\" data-end=\"9089\"\u003e\n\u003cp data-start=\"8932\" data-end=\"9089\"\u003e\u003cstrong data-start=\"8932\" data-end=\"8952\"\u003eContext reviews:\u003c\/strong\u003e Triple-agonist reviews outlining rationale for \u003cstrong data-start=\"9000\" data-end=\"9018\"\u003eGLP-1\/GIP\/GCGR\u003c\/strong\u003e combinations (without IGF-1R).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684850889042,"sku":null,"price":200.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/bioglutide100mg.png?v=1770834837","url":"https:\/\/sciencepeptideslab.com\/products\/bioglutide","provider":"Science Peptides Lab","version":"1.0","type":"link"}